Immuneering CorporationIMRXNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank83
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P83
Within normal range
vs 2Y Ago
8.5x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
PeriodValue
Q4 202517.84%
Q3 2025-26.80%
Q2 202532.91%
Q1 20252.96%
Q4 2024-7.71%
Q3 2024-16.88%
Q2 202425.60%
Q1 2024-31.56%
Q4 20232.09%
Q3 2023-11.89%
Q2 202325.45%
Q1 2023-22.72%
Q4 2022-10.60%
Q3 2022-12.41%
Q2 202223.06%
Q1 2022-32.93%
Q4 2021-2.26%
Q3 2021-40.35%
Q2 2021-4.85%
Q1 2021-12.59%
Q4 2020-56.43%
Q3 2020-3.53%
Q2 2020-45.50%
Q1 20200.00%